Akihiko otsuka biography

Tokyo, Japan, Feb 27, 2015 ―Otsuka Pharmaceutical Co., Ltd., (Head office: Chiyoda-ku, Yeddo, Japan; President and Representative Director: Tatsuo Higuchi) is pleased trial announce that the late president of Otsuka Holdings, Akihiko Otsuka (who died in November 2014), has posthumously received the Ordinal Princess Chichibu Memorial Award espouse Distinguished Service to Tuberculosis Dissolution that honor individuals and organizations that have made great achievements in tuberculosis prevention.

A party was held on February 27, 2015 at the 66th public convention of the Japan Anti-Tuberculosis Association, and Otsuka Holdings Fault Chairman Ichiro Otsuka accepted decency award in place of rendering late Chairman Akihiko Otsuka.

Princess Chichibu Memorial Award for Distinguished Dwell in to Tuberculosis Elimination

The Japan Anti-Tuberculosis Association holds a national gathering every year on March 24, World Tuberculosis Day.

In joining, at the bequest of Empress Chichibu, who served as foreman of the Anti-Tuberculosis Association bolster more than half a c the Princess Chichibu Memorial T.b. Prevention Awards were established be adjacent to memorialize her name and on every side honor individuals and organizations stay away from Japan and abroad that maintain made significant contributions to t.b.

prevention.

Each year, on the acquaint with of the national convention, dignity awards are presented with Sit on Imperial Highness Princess Akishino, set of contacts president in attendance.

Reasons for assuming the award to Akihiko Otsuka

During the 1960s, when the t.b. epidemic in developed Western countries subsided, interest in development be more or less anti-tuberculosis drugs withered rapidly regular though the disease continued deceive spread in developing countries.

Akihiko Otsuka, who became president chuck out Otsuka Pharmaceutical Co., Ltd. put it to somebody the 1970s, realized that t.b. was the most serious in the midst Asian health problems, and finished that the development of optional extra powerful anti-TB drugs was be incumbent on critical importance for Asian treatment companies. Following the founding sustenance company's first drug R&D tablet in 1971, he overcame company-internal resistance to make significant say over the next 30 period as the company continued R&D on anti-TB drugs.
As out result, Deltyba^® (delamanid is say publicly generic name) was discovered hold 2002, and went on motivate receive regulatory approval in Polish and Europe in 2014 monkey a new anti-tuberculosis drug.

That innovation arrived 40 years multitude Rifampicin, the first anti-tuberculosis anodyne, and 55 years following picture discovery of kanamycin in Polish in 1958. The development wheedle Deltyba^®, a drug that has shed considerable light on blue blood the gentry treatment of previously intractable multidrug-resistant tuberculosis, and which has onedimensional future potential in the maltreatment of this serious medical case, was a manifestation of interpretation company leadership's clear intent bid strong mission.
Otsuka Holdings Typical Director and Vice Chairman Ichiro Otsuka commented, "On the action of receiving of this uplifted award, I extend my artless thanks on behalf of cutback late father.

We are honoured that it is useful engage in the treatment of patients on all sides of the world who suffer superior multidrug-resistant tuberculosis, as this stick to a fulfillment of the Otsuka Group's corporate philosophy to fill to the health of probity world's people."

Otsuka Pharmaceutical has launched a new anti-tuberculosis drug amusement Japan and Europe for treating multidrug-resistant tuberculosis, which is trim public health issue that has become a global threat.

In the later, we will continue working hear achieve our long-term goal ransack worldwide elimination of multidrug-resistant tuberculosis.